Follicle-stimulating hormone (FSH) exists in multiple molecular forms. In both experimental animals and in humans the production and secretion of less acidic, short-lived FSH glycoforms significantly increase during the peri-ovulatory period. To gain further insights on the physiological role of these FSH variants, we analysed the ability of two FSH compounds, recombinant FSH (rFSH) and purified FSH from urinary origin (uFSH), (less acidic and acidic pattern of FSH charge isoform distributors respectively) to induce ovarian tissue-type plasminogen activator (tPA) enzyme activity in vivo. FSH produced by Chinese hamster ovary cells and highly purified uFSH were injected at 15:00 h on the pro-oestrous day into phenobarbital-blocked rats and the ovaries were analysed for tPA enzyme activity and tPA mRNA concentrations at different times after FSH injection. Induction of tPA enzyme activity by uFSH and rFSH showed distinct dynamics depending on the particular preparation administered. In animals treated with uFSH, maximum tPA enzyme activity was detected at 20:00 h, and maximum tPA mRNA concentrations were detected at 17:00 h. tPA enzyme activity induction by rFSH was at the maximum at 17:00 h, and maximum tPA mRNA concentration was at 16:00 h (P < 0.05 for uFSH versus rFSH). All animals in the uFSH-and rFSH-treated groups and none in phenobarbitalblocked, saline-treated controls ovulated. No significant differences were present in the number of ova shed by rats treated with uFSH or rFSH and spontaneously ovulating rats (10.7 ⍨ 1.7, 10.0 ⍨ 2.6 and 11.3 ⍨ 1.6 respectively). These data indicate that the increased biological activity exhibited by less acidic FSH glycovariants at the target cell level may compensate for the drawback imposed by their relatively short plasma half-life.
Introduction
Follicle stimulating hormone (FSH) is a structurally complex glycoprotein hormone synthesized by the anterior pituitary gland. Like other glycoprotein hormones, luteinizing hormone (LH) and thyroid stimulating hormone (TSH), FSH exists as a family of isohormones which have been identified within the anterior pituitary and serum of several mammalian species, including man (Ulloa- Aguirre et al., 1988 Aguirre et al., , 1992a Aguirre et al., , 1995 Stanton et al., 1996) . Since post-translational oligosaccharide modifications, such as terminal sialylation and to a lesser extent terminal sulphation, distinguish most of the FSH isoforms, changes in pituitary and circulating FSH isoform mixtures can be easily identified by techniques that separate the isoforms on the basis of charge (Ulloa-Aguirre et al., 1995) . As a consequence of their carbohydrate-based structural differences, FSH isoforms differ in their ability to bind to target cell receptors, survive in the circulation and provoke a biological response in vivo and in vitro. More acidic/sialylated isoforms exhibit higher plasma half-lives but lower in-vitro biological and receptor-binding activity/immunoactivity relationships than their less acidic counterparts (Wide, 1986;  1032 © European Society for Human Reproduction and Embryology Wide and Hobson, 1986; Ulloa-Aguirre et al., 1992a; Zambrano et al., 1996) .
In both experimental animals and humans, the charge isoform distribution of FSH changes depending on the physiological status of the donor (Ulloa- Aguirre et al., 1995) . In regularly cycling women, a selective increase in the relative abundance of circulating less acidic (and presumably less sialylated) FSH charge isoforms has been consistently detected during the late follicular phase and mid-cycle of the menstrual cycle (Padmanabhan et al., 1988; Wide and Bakos, 1993; Zambrano et al., 1995) . Further, in one of these studies an increased concentration of less acidic isoforms at mid-cycle was temporarily associated with a marked decrease in the calculated plasma half-life of endogenously secreted FSH, thus suggesting that this shift towards less acidic/sialylated isoforms may potentially decrease the in-vivo biopotency of the gonadotrophic signal released from the pituitary during this particular cycle phase (Zambrano et al., 1995) . Considering that the overall effects in vivo of a given endocrine signal acting on target tissues remote from its gland of origin depends on the interplay of several factors, including its plasma half-life, receptor-binding affinity and capability of the ligand to activate its receptor and trigger intracellular signal transduction, we have previously postulated that such a decrease in in-vivo biopotency of the less acidic FSH isoforms may be counteracted by their enhanced capability to induce a biological effect at the target cell level, as indicated by studies employing either heterologous or homologous in-vitro bioassay systems (UlloaAguirre et al., 1995; Zambrano et al., 1996) . It is therefore possible that less acidic/sialylated FSH isoforms may induce a potent, albeit shorter-lived, effect on the target cell in in-vivo conditions and behave as an effective agonist of FSH action.
Analysis of the above proposal has been hampered by the fact that the end point of the assays generally employed to test the in-vivo biopotency of FSH [e.g. the rat ovarian weight augmentation assay (Steelman and Pohley, 1953) ] is highly dependent on the half-life of the hormone and thus may not provide information on the potential for an acutely inducible effect of a given short-lived isoform. For instance, the invivo biopotency of the less acidic FSH isoforms is almost undetectable by classical ovarian weight augmentation bioassays and this reduced biopotency closely correlates with their corresponding low plasma half-life (Wide, 1986; Wide and Hobson, 1986) . These findings, however, do not necessarily mean that under certain physiological conditions or in terms of other functional end points the presence of the less acidic FSH isoforms in the circulation is irrelevant.
To address this issue, we analysed the capacity of two different FSH preparations to acutely induce ovarian tissuetype plasminogen activator (tPA) enzyme activity, an event closely involved in follicular rupture and ovulation (Beers et al., 1975; Strickland and Beers, 1976; Reich et al., 1985; Liu et al., 1987; Galway et al., 1990; Shen et al., 1997) . Because of the unavailability of highly purified naturally occurring FSH isoforms, we used two highly purified FSH preparations, devoid of LH activity (which may also induce tPA enzyme activity), which exhibit distinctly different charge isoform distributions (Lambert et al., 1995; Ulloa-Aguirre et al., 1997) . Phenobarbital-blocked pro-oestrous rats were challenged with highly purified human urinary FSH (uFSH) or recombinant FSH (rFSH) [acidic and less acidic (or relatively basic) pattern of FSH charge isoform distribution respectively] and the effects of these FSH preparations on ovarian tPA enzyme activity and tPA mRNA concentrations were then analysed. 
Materials and methods

FSH material
Chromatofocusing (CF) of FSH preparations
Chromatofocusing of uFSH and rFSH was performed as described previously (Ulloa-Aguirre et al., 1995b) . Briefly, columns (30ϫ1 cm) of polybuffer exchange resin (PBE 94, Pharmacia Fine Chemicals, Piscaway, NJ, USA) were constructed and equilibrated with 15 bed volumes of starting buffer (0.025 M imidazole-HCl/l, pH 7.4). Thereafter, a highly concentrated amount [125 IU dissolved in eluent buffer (1:8 dilution of Polybuffer 74 (Pharmacia) in deonized water, pH 4.0)] of uFSH or rFSH was applied on the top of the column. Eluent buffer (5 ml) was run before sample application to avoid exposure of the sample proteins to extremes of pH. The pH of each fraction (collected at a flow rate of 1 ml/4 min at 4°C) was measured, and, when stabilized at its lowest value, the eluent buffer was changed to a 1.0 M NaCl solution to recover those proteins bound at the lower limiting pH (salt peak). Each fraction was stored frozen at -20°C until the FSH determination by radioimmunoassay. The recovery of FSH was~80% of the total amount applied to the column.
In-vitro bioassay of FSH
Bioactive FSH was measured using the in-vitro granulosa cell aromatase bioassay (GAB) (Jia et al., 1985) . Granulosa cells obtained from immature diethylstilboestrol (DES)-treated Wistar rats were cultured in 24-well, 16 mm plates containing~120 000 cells/ well in 500 µl McCoy's 5a (Gibco BRL, Gaithersburg, MD, USA) medium containing 10 -7 M DES, 0.125 M 1-methyl-3-isobutylxanthine, 2 mM glutamine, 10 -6 M androstenedione (Sigma Chemical Co, St Louis, MO, USA), 100 U/ml penicillin and 100 µg/ ml streptomycin (Gibco), 1 µg/ml bovine insulin (Elly Lilly de México, Mexico D.F., Mexico) and increasing immunoactive concentrations (0-200 ng/well) of uFSH, rFSH or LER-907. After a 72 h incubation period, the media were collected and stored frozen until quantification of oestradiol by radioimmunoassay. Results are expressed as the bioactivity:immunoactivity (B:I) ratio, i.e. the ratio of activity in the in-vitro bioassay relative to the activity in the radioimmunoassay.
Radioimmunoassays
FSH
Purified human FSH (FSH-I3; NIDDK) was iodinated as previously described (Timossi et al., 1998) . The assay was performed using reagents provided by the NIDDK; the reference preparation LER-907 was used to construct the standard curve and the polyclonal antihuman FSH-6 at a final dilution 1:250 000 was used as antiserum. The cross-reactivity of this antiserum with human LH was Ͻ0.1% and the free alpha subunit was practically undetectable. To avoid interassay variations all fractions from a single CF separation were assayed (in duplicate) in the same batch. Intra-assay variability was Ͻ8%.
Oestradiol
The amount of oestradiol produced in vitro in the GAB was measured by radioimmunoassy using an antiserum against oestradiol-17β kindly provided by the Cuba-México World Health Organization RIA Reagents Program (México). Because of the significant crossreactivity of this antiserum with oestrone, results are expressed as ng of total oestrogens produced. The sensitivity of the assay was 6.3 pg/reaction. To avoid interassay variations, all samples from a single GAB were assayed in the same radioimmunoassay batch; the intraassay coefficient of variation was Ͻ6%.
Detection of tPA enzyme activity
Detection of tPA enzyme activity was assessed by zymography following the method of Granelly-Piperno and Reich (1978) as modified by Heussen and Dowdle (1980) . Briefly, rat ovaries were homogenized in phosphate (0.05 M)-buffered (0.15 M) saline (PBS), pH 7.4, containing 0.01% Tween-80 and then centrifuged at 1000 g for 15 min at 4°C. The supernatant fractions were obtained and their protein content determined by the method of Bradford (1976) . Equal quantities (~0.5 mg) of each sample were electrophoresed in 12% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) slab minigels for 1.5 h at 4°C. Each SDS-PAGE involved two gels, the first contained 1.5 mg/ml gelatin to detect nonplasminogen-dependent proteases and the second contained both gelatin and 160 µg/ml purified human plasminogen (Sigma) to detect plasminogen-dependent proteases. Purified recombinant tPA (M r 70 000) and urokinase-type plasminogen activator (M r~5 0 000) were also applied to each gel as reference standards. After electrophoresis, gels were washed three times with 2.5% Triton X-100 in 50 mM Tris-HCl, pH 8.0, during 1 h at room temperature and then incubated for 16-18 h at 37°C, fixed, stained with 0.1% Coomasie Blue R-250 in 40% methanol, 10% acetic acid and 50% deionized water and photographed. Semiquantitative estimation of protease activity was performed by densitometric scanning using an Eagle Eye II video imaging system (Stratagene, La Jolla, CA, USA). Since the urokinase-type plasminogen activator enzyme activity was not altered by exogenous FSH administration (Ny et al., 1985; Liu et al., 1987) , relative amounts of tPA enzyme activity were normalized against the corresponding urokinase-type plasminogen activatordependent protease activity in the same blot. Results are expressed as the relative ratios between treatment and control (phenobarbital/ saline-treated) groups by setting the normalized tPA-dependent protease activity of each control group at an arbitrary level of 1.0. The above procedures enabled correction for both differences in the amount of sample applied to the gel and subtle changes in tPAdependent protease activity which may occur independently of the exogenous FSH challenge. In the experiments on the time course of ovarian tPA enzyme activity throughout the day of pro-oestrus, semiquantitative estimation of protease activity was performed by measuring the areas of the lytic zones (heightϫwidth).
RNA isolation, electrophoresis and blot hybridization
Total RNA from rat ovaries was isolated by standard methods (Chomczynski and Sacchi, 1987) . Final RNA pellets were resuspended in DEPC-treated water, and the amount of RNA extracted was determined by optical density at 260 nm. Samples containing 15 µg total RNA were electrophoresed in 1% formaldehyde-agarose gels and transferred to nylon membranes (Z-probe; Bio-Rad Labs, CA, USA). After UV cross-linking, membranes were hybridized with a tPA-cDNA 32 P-labelled probe (provided by Dr Tor Ny, University of Umea, Umea, Sweden) in hybridization solution (1 mM EDTA, 0.15 M NaHPO 4 , 7% SDS, pH 8.0) at 56°C for 18-24 h and then washed with 0.1% SDS at room temperature. Filters were exposed to Kodak XAR-5 film during 72 h at 70°C. To confirm that equal amounts of total RNA were loaded, each blot was hybridized with 32 P-labelled rat cyclophylin cDNA. Both cDNA probes were radiolabelled using a commercial random primer DNA labelling kit (Gibco). Labelled bands were quantified by densitometric analysis of autoradiograms; relative amounts of tPA mRNA were normalized against corresponding amounts of cyclophylin mRNA on the same blot. Results are presented as the relative ratios between treatment and control (phenobarbital/saline-treated) groups by setting the normalized tPA mRNA of each control group at an arbitrary level of 1.0.
Disappearence of uFSH and rFSH from rat circulation
Adult Long-Evans male rats weighing 400-450 g were used for studies of the disappearance of each FSH preparation from plasma. For this purpose, a jugular vein was cannulated under ether anaesthesia. Approximately 60 µg (Ulloa- Aguirre et al., 1992b Aguirre et al., , 1995b of immunoactive uFSH or rFSH were slowly injected i.v. and blood samples (150 µl) were taken at 5 and 10 min after the injection and subsequently at regular time intervals (10-60 min) during the ensuing 4 h. After each bleeding, the circulating volume was maintained with 0.9% NaCl. Blood samples were left to clot at 4°C and then centrifuged at 1000 g for 15 min. Serum was removed and stored frozen at -20°C until the fluoroimmunoassay of human FSH (DELFIA; Wallac OY, Turku, Finland; cross-reactivity with rat FSH Ͻ0.01%).
In-vivo induction of tPA enzyme activity and tPA mRNA by uFSH and rFSH Adult female rats of the CIIZ-V strain were maintained in groups of five animals under light-controlled conditions (lights on from 05:00 to 19:00 h) with pelleted food and water provided ad libitum. Only those rats that had shown two consecutive 4 day cycles, determined by daily vaginal smear, were included in the experiments. The pattern of serum gonadotrophin concentrations throughout the oestrous cycle of this particular strain of rats has been reported elsewhere (UlloaAguirre et al., 1985) . At 09:00 h on the pro-oestrous day, the animals were distributed in 15 groups of five rats each and assigned randomly to the different treatments. At 12:00 h, each animal was treated with phenobarbital (10 mg/100 g body weight, i.p.) to block the endogenous surge of gonadotrophin releasing hormone and gonadotrophins (Rance and Barraclough, 1981) . Three hours later (at 15:00 h), five animals were killed by decapitation and the remaining animals received an intracardiac injection of 60 µg immunoactive uFSH, rFSH [dissolved in 100 µl saline (0.9%) solution] or saline solution; thereafter, sets of five animals per treatment group were subsequently decapitated at 16:00 h, 17:00 h, 20:00 h and 23:00 h and at 03:00 h on the day of oestrus. Ovaries were dissected, weighed and immediately frozen and maintained at -70°C until processing for tPA enzyme activity determination and measurement of tPA mRNA content. In those animals killed at 03:00 h on the day of oestrus, oviducts were dissected and ova counted using a dissecting microscope. In a separate experiment, groups of five rats were killed every 2 h from 09:00 h on the day of pro-oestrus to 03:00 h on the day of oestrus; the ovaries and oviducts (only in those animals killed at 03:00 h on the day of oestrus) were dissected and processed as described above.
Statistical analysis
One-way analysis of variance (ANOVA) for repeated measures (for n Ͼ 3) and the unpaired t-test (for n ϭ 2) were used to analyse differences between groups. When the ANOVA disclosed significant differences, t-tests were used to determine which means were different. The pharmacokinetic parameters plasma half-life (T 0.5 ), mean residence time (MRT) and plasma clearance rate were calculated using an interactive computer program for statistical and pharmacokinetic analysis of data (PKCALC) (Shumaker, 1986) as described elsewhere (Ulloa-Aguirre et al., 1992a) . P Ͻ 0.05 was considered statistically significant. values ഛ4.50 (including the salt peak) whereas in rFSH Ͻ50% of total immunoactivity recovered was detected within these values. For both preparations, no FSH immunoactivity was detected at pH values Ͼ5.60.
Results
Charge distribution profile of uFSH and rFSH
In-vitro bioactivity and pharmacokinetic behaviour of uFSH and rFSH
Both human FSH preparations induced significant and parallel curves for dose-dependent oestrogen production when analysed in equivalent immunoactive amounts in the GAB (Figure 2) . In this assay, the in-vitro bioactivity of pituitary FSH contained in the LER-907 standard was lower than those induced by rFSH and uFSH, as indicated by the shift to the right of its corresponding dose-response curve. The resultant in-vitro biopotency of rFSH was higher (P Ͻ 0.05) than that exhibited by uFSH (bioactive:immunoactive ratios 2.47 Ϯ 0.21 versus 1.99 Ϯ 0.03; 0 Ϯ SD, n ϭ 3). Figure 3 shows representative plasma disappearance curves for uFSH and rFSH. The first sample (5 min) was considered 100% at x ϭ 0. As shown in the figure, the disappearance rate of uFSH was slower than that of the less acidic preparation (rFSH). Similar differences between rFSH and uFSH were found in the pharmacokinetic parameters plasma clearance rate (0.34 Ϯ 0.09 versus 0.14 Ϯ 0.01 ml/ min), MRT (105 Ϯ 21 versus 168 Ϯ 17 min) and T 0.5 (76 Ϯ 12 versus 116 Ϯ 11 min) as well as in the percentage of immunoactive FSH recovered at 240 min (9.1 Ϯ 3.3 versus 21 Ϯ 1.5%) (P Ͻ 0.05 for all parameters).
tPA enzyme activity and tPA mRNA concentrations in ovaries from rats treated with uFSH or rFSH
Ovaries from pro-oestrous animals (not treated with phenobarbital or FSH) presented maximum tPA enzyme activity at 21:00 h (Figure 4) , whereas in phenobarbital-blocked prooestrous rats induction of ovarian tPA enzyme activity by uFSH and rFSH showed distinct dynamics depending on the particular preparation administered ( Figure 5 ). In animals treated with the more acidic preparation (uFSH), maximum proteolytic activity and tPA mRNA concentrations were detected at 20:00 h and 17:00 h respectively, whereas in those treated with rFSH induction of tPA enzyme activity occurred earlier, with a maximum activity detected at 17:00 h, 2 h after rFSH administration; in these animals, a significant increase in tPA mRNA concentrations preceded by 1 h the appearance of maximum protease activity ( Figure 5 A and B) . In all experiments, no proteolytic activity with M r~7 0 000 or M r 50 000 was detected when plasminogen was omitted from the polyacrylamide gels (not shown).
As expected, all animals in the uFSH-and rFSH-treated groups and none in the phenobarbital-blocked, saline-treated controls ovulated. The number of ova shed by rats treated with uFSH or rFSH was not significantly different (Table I) .
Discussion
In the present study we have have tested the ability of two different FSH preparations for an acutely inducible effect in in-vivo conditions. Each FSH preparation exhibited distinct charge isoform distribution, in-vitro biological activity and plasma pharmacokinetic behaviour. The highly purified uFSH compound was more acidic, exhibited lower in-vitro biological Figure 5 . Induction of ovarian tissue-type plasminogen activator (tPA) mRNA (A) and tPA enzyme activity (tPAae) (B) after administration of urinary follicle stimulating hormone (uFSH) or recombinant FSH (rFSH) to phenobarbital-blocked pro-oestrous rats. Rats were treated with phenobarbital at 12:00 h on the day of pro-oestrus and then with saline solution, uFSH or rFSH. Ovaries collected at each time point were examined for tPA enzyme activity and expression as described in the text. Also shown are corresponding kinetic curves for tPA enzyme activity as disclosed by fifth order linear regression. Values are the mean Ϯ SEM of three independent studies. Different letters above symbols or bars indicate the existence of significant (P Ͻ 0.05) differences within each treatment group (rFSH or uFSH). potency and remained longer in the circulation than recombinant FSH produced in CHO cells, thus confirming and extending previous studies (Lambert et al., 1995) . Variations in the structure and distribution of sialylated and, to a lesser extent, sulphated asparagine-linked oligosaccharides, imposed by the particular origin of each preparation, may account for the differences observed between the two preparations. In fact, highly purified uFSH is obtained from samples of postmenopausal women, whose pituitary contains and secretes more acidic FSH isoforms in comparison to glands of women in fertile age (Wide, 1982 (Wide, , 1985 ; in addition, this particular preparation is subjected to a highly rigorous purification process during which some less acidic forms may have been removed (Barri et al., 1993) . In contrast, the rFSH pH distribution profile tended to be limited to a smaller range, which may be attributed to restriction in glycosylation by the CHO cells. Indeed, it has been shown that rFSH produced by a human cell line may exhibit a more wide charge distribution profile that resembles the spectrum found within the pituitary gland (Flack et al., 1994) . It has been demonstrated that plasminogen activators from ovarian origin are closely linked to the ovulatory process (Beers et al., 1975; Strickland and Beers., 1976; Reich et al., 1985) . In particular, tPA mRNA and enzyme activity dramatically increased during the peri-ovulatory period in hypophysectomized, pregnant mare serum gonadotrophin-primed immature rats treated with FSH or human chorionic gonadotrophin, 12 h after the ovulatory stimuli (Liu et al, 1987; Galway et al., 1990; Shen et al., 1997) . In the mature rat, plasminogen activator activity significantly increased on the evening (at 20:00 h) of pro-oestrus and this rise in enzyme activity could be abolished by pharmacological blocking of the endogenous gonadotrophin surge (Reich et al., 1985) . Moreover, in the present study we found that a dramatic and sustained increase in tPA mRNA concentrations, occurring around the time of the endogenous gonadotrophin surge, preceded by~2 h the gradual increase in tPA enzyme activity observed during the late afternoon and evening (at 17:00 to 21:00 h) of pro-oestrous, further emphasizing the role of the gonadotrophin signal on the acute generation of activators of the proteolytic cascade that eventually leads to follicle rupture and ovulation.
Although both rFSH and uFSH were able to acutely induce tPA mRNA and tPA enzyme activity in phenobarbital-blocked pro-oestrous rats, the kinetics of the induction differed between the two compounds, with the less acidic preparation (rFSH) triggering both events earlier than its more acidic counterpart. Since the peptide sequences of both FSH species are practically identical, the only explanation for this finding may be the presence of variations in oligosaccharide structure, which has been emphasized by several investigators (Hard et al., 1990; Lambert et al., 1995; Rafferty et al., 1995; de Leeuw et al., 1996; Olijve et al., 1996) . In fact, the particular charge isoform distribution (de Leeuw et al., 1996) and differences in capability to interact with various lectins (Rafferti et al., 1995) indicate that recombinant DNA-derived FSH may be less sialylated and possess less complex branched oligosaccharide structures than the highly purified urinary preparation. How these variations in carbohydrate structure affect the effectiveness of each FSH variant to activate its cognate effector system and trigger diverse intracellular signalling pathways is a matter of speculation at this time. Nevertheless, recent studies employing underglycosylated FSH variants have indicated that particular ligand glycosylation-dependent changes in receptor conformation may lead to different or even disparate activation of intracellular signals (Arey et al., 1997; Timossi et al., 1998) .
The different kinetics by which less and more acidic FSH species induce an acute effect in vivo have several implications. From the physiological point of view, the finding that FSH species with pH values Ͼ4.50 are highly effective to acutely induce tPA enzyme activity gives further support to previous hypotheses on the possible physiological role of the increased secretion of less acidic, short-lived FSH isoforms during the peri-ovulatory period (Ulloa-Aguirre et al., 1995; Zambrano et al., 1995) . These less acidic (pH Ͼ4.50) isoforms may participate in the induction of plasminogen activator which, by activating plasmin, leads to the final breakdown of collagen in ovulating follicles. The short plasma half-life of these variants would ensure induction of an acute effect, without interfering with the normal development of the cohort of follicles destined to be recruited during the following cycle (Fauser and van Heusden, 1997) . On the other hand, the fact that less acidic FSH isoforms (as those present in rFSH) exhibit a higher in-vitro biopotency than uFSH (Ulloa-Aguirre et al., 1992a Lambert et al., 1995) and behave as full agonists in vivo despite having relatively accelerated plasma disappearance rates (Ulloa-Aguirre et al., 1992a; de Leeuw et al., 1996) , give a partial explanation to recent findings indicating that rFSH may be more efficient than urinary FSH (including its highly purified variant) for ovarian hyperstimulation in women undergoing in-vitro fertilization (Out et al., 1996; Bergh et al., 1997) . Finally, a recent study advocates the use of quantitative isoelectric focusing to predict the invivo biological activity of human FSH (Mulders et al., 1997) . Because such studies have been based exclusively on the behaviour of the different rFSH charge isoforms in the low sensitivy ovarian weight augmentation assay (which depends highly on the plasma disappearance rate of the glycoprotein), without taking into account the potency of the isoforms at the target cell level or other acutely inducible in-vivo effects, the assumption that the charge distribution profile may be taken as an estimation of the in-vivo potency of a given FSH preparation should be exercised with caution.
In summary, rFSH produced by CHO cells has a less acidic charge distribution profile, exhibits higher in-vitro bioactivity and plasma clearence rate and induces tPA enzyme activity more rapidly than a highly acidic FSH preparation from urinary origin. Apparently, the high biological activity that the rFSH glycoforms exhibit at the target cell level may compensate and even surpass the drawback imposed by their relatively shorter plasma half-life. Further studies employing highly purified, naturally occurring FSH variants are still necessary to finally assign a physiological role to the variations in isoform secretion normally occurring during the human menstrual cycle.
